Ubs Asset Management Americas Inc Iovance Biotherapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,994,500 shares of IOVA stock, worth $22 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,994,500
Previous 179,850
1008.98%
Holding current value
$22 Million
Previous $2.67 Million
500.19%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding IOVA
# of Institutions
320Shares Held
238MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$286 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$286 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$265 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$234 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$139 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.74B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...